Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

URB754

Supposed MAGL inhibitor: the activity came from a mercury impurity in the commercial batch; reported in 2013 in illegal products in Japan.

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₁₆H₁₄N₂O₂

CAS 86672-58-4

Family
ECS pharmacological toolEnzyme inhibitor
Molar mass
266.29 g/mol

Updated on

In plain terms

URB754 was presented in 2005 as a blocker of an enzyme of the cannabinoid system, and the effect then turned out to come from a mercury impurity in the commercial sample: the molecule itself does not block this enzyme. It has also been found in Japan in illegal products sold as designer drugs. It is a textbook case of reagent error.

Receptors and activity

Target network

MAGLModulatorno inhibition found (rat brain, Saario et al. 2006; recombinant human MAGL, Vandevoorde et al. 2007); the activity reported in 2005 (IC50 200 nM) comes from an impurity (Tarzia et al. 2007)
  • Binds or modulates

The lower the cited value, the closer the target sits to URB754: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of URB754.

Brain, side view
Body, front view
Blood

MAGLMAGL found in 5 regions of the body

  1. CortexdenseHighest PET signal in the cerebral cortex1
  2. Basal gangliapresentModerate levels in the putamen1
  3. HippocampuspresentAxon terminals in the hippocampus2
  4. Adipose tissuepresentPresent in subcutaneous adipose tissue3
  5. Immune cellspresentRNA enhanced in blood monocytes4

Cited values

  1. MAGLModulatorno measured value cited

    no inhibition found (rat brain, Saario et al. 2006; recombinant human MAGL, Vandevoorde et al. 2007); the activity reported in 2005 (IC50 200 nM) comes from an impurity (Tarzia et al. 2007)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

URB754 is interesting for what it is not. Arising from the screening of a commercial chemical library, it was reported in 2005 in Nature Neuroscience as a potent inhibitor of monoacylglycerol lipase (MAGL) (Makara et al. 2005). The correction came in two stages. In 2006, Saario et al., at the University of Kuopio, found no inhibition of 2-AG hydrolysis or of FAAH in rat brain, and concluded that the compound could not serve as a starting point for developing MAGL inhibitors (Saario et al. 2006). In 2007, analysis of the commercial sample by HPLC/MS, NMR and EI/MS showed that the activity attributed to URB754 was due to an impurity, bis(methylthio)mercurane, with an IC50 of 11.9 nM on MAGL (Tarzia et al. 2007). An erratum was published for the 2005 article in January 2007 (Nat Neurosci 10:134). The same year, Vandevoorde et al. observed no effect on recombinant human MAGL (Vandevoorde et al. 2007). The compound was also reported in 2013 in illegal products in Japan, together with 4-methylbuphedrone (Uchiyama et al. 2013). No pharmacokinetic, metabolic or human data were found in the sources consulted.

History

Source
Entirely synthetic compound with no known natural occurrence. It served as a laboratory reagent, but it was also reported in 2013 as a « new type of designer drug » in illegal products detected in Japan, together with 4-methylbuphedrone (Uchiyama et al. 2013). The activity that had given it its pharmacological interest was not its own.

Origin

Research tool

No known biosynthetic pathway: a synthetic molecule. It is a benzoxazinone, 6-methyl-2-(4-methylanilino)-3,1-benzoxazin-4-one.

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Enzyme inhibitor

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

URB754 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

IUPAC name
6-methyl-2-(4-methylanilino)-3,1-benzoxazin-4-one
Other names
URB 754 · URB-754

Identifiers

Formula
C₁₆H₁₄N₂O₂
CAS
86672-58-4
PubChem CID
848487(new tab)
InChIKey
GFWNGVKCDGYFKG-UHFFFAOYSA-N
SMILES
CC1=CC=C(C=C1)NC2=NC3=C(C=C(C=C3)C)C(=O)O2

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.